A retrospective single-center study to determine real world experience of dacomitinib in EGFR mutated advanced NSCLC patients
Latest Information Update: 24 Jul 2021
At a glance
- Drugs Dacomitinib (Primary)
- Indications Adenocarcinoma; Adenosquamous carcinoma; Brain metastases; Non-small cell lung cancer; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- 24 Jul 2021 New trial record
- 08 Jun 2021 Results presented at the 57th Annual Meeting of the American Society of Clinical Oncology